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Pitfalls associated with lipophilic fluorophore staining of extracellular vesicles
for uptake studies
Jens B. Simonsen
Department of Health Technology (DTU Health Tech) and Department of Micro- and Nanotechnology (DTU Nanotech), Technical University
of Denmark, Lyngby, Denmark
ABSTRACT
Post-staining of extracellular vesicles (EVs) with lipid-anchored fluorophores (LAFs) such as
PKH67 is a widely used strategy for studying EVs but it is associated with several pitfalls. The
pitfalls discussed in this commentary are related to LAF labelling of non-EV species due to (1)
lipoprotein contamination in EV samples, (2) desorption of the LAF reporters from vesicles
into proteins and lipoproteins in blood and serum, and (3) the capability of the amphiphilic
LAF compounds to form EV-like particles. Awareness of these challenges and developing
solutions to overcome these are important to ensure that we make relevant interpretations
when using LAFs to track EVs.
ARTICLE HISTORY
Received 21 December 2018
Revised 1 February 2019
Accepted 9 February 2019
KEYWORDS
Extracellular vesicles;
fluorophores; staining;
labelling; dissociation;
contamination; lipoproteins;
targeting; uptake; tracking
Extracellular vesicles (EVs) have gained considerable
attention over the last decade due to their targeting
potential and long-range cell-to-cell communication
properties [1,2], as well as their proposed clinical poten-
tial as disease biomarkers [3,4] and drug delivery systems
[5–7]. These spherical biological nanoparticles (~30–
1000 nm) are comprised of a lipid membrane containing
membrane-bound proteins, and an aqueous core capable
of carrying biological cargo, such as nucleic acids, pro-
teins and other biomolecules, and are secreted from most
types of cells into most types of bodily fluids [8–10].
A wide range of in vitro and in vivo techniques are used
to gain insight into the biological functions of EVs,
including flow cytometry, confocal microscopy and
in vivo fluorescence-detection techniques. While these
techniques can reveal information about the internaliza-
tion of EVs by cells or tissues, they also rely on fluorescent
reporters associated to the EVs. One widely used method
to achieve this is by post-inserting lipid-anchored fluor-
ophores (LAFs) into the EV membrane.
When LAFs are post-inserted into EVs, the outcome is
typically LAF-labelled EVs and free LAFs in solution. To
remove free LAFs (that could pose a challenge to EV-based
uptake studies) from the LAF-labelled EVs various types of
physical-based methods are used, including spin filtration,
size-exclusion chromatography, ultracentrifugation and
density gradient centrifugation. However, more compli-
cated challenges beyond the presence of free LAFs after
staining the EVs exist. A challenge that is far less known
and appreciated in the field, is the concomitant labelling of
non-EV particles in addition to EVs [11,12]. Importantly,
the danger of labelling non-EV particles remains even
when purified stained vesicles samples are used [13].
These not-so-known pitfalls related to unintended LAF
labelling of non-EV species including LAF dissociation
from vesicles were recently reported [13]. Thus, I find it
timely and very important to highlight and bring together
these essential staining issues in an integrated manner and
provide some tentative solutions to overcome these chal-
lenges. I would also like to stress that the presence of non-
EV LAF-labelled particles in EV-based uptake and biodis-
tribution studies that rely on the LAF-fluorescence will
likely distort the outcome of the experiments and lead to
wrong conclusions about the targeting properties and bio-
logical fate of EVs.
Several studies have highlighted the high degree of lipo-
protein contamination in ostensibly purified EV samples
obtained from plasma [14,15]. The similarity in physical
properties between EVs and different types of lipoproteins
[16], and the ~6 orders of magnitude higher concentration
of lipoproteins relative to EVs in human plasma [17] com-
monly lead to high lipoprotein contamination in EV iso-
lates from plasma when using physical-based isolation
methods. Likewise, EV isolates from cell culture medium
are also prone to lipoprotein contamination when serum
(incl. EV-depleted serum) has been present during the EV
production. Thus, the typical EV isolate likely contains
lipoproteins that are comprised of a lipid monolayer at
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their surface and can, therefore, compete with the EVs for
incorporating the hydrophobic LAF labels. This fact is
indeed a challenge because LAF labelling is also used to
investigate the cellular uptake of various lipoprotein parti-
cles, including very low-density lipoproteins (VLDL) [18],
low-density lipoproteins (LDL) [19] and high-density lipo-
proteins (HDL) [20]. The unintended LAF labelling of the
different types of bio-nanoparticles including lipoproteins
in an apparently pure EV sample [11] is shown in path (a)
of Figure 1.
In an ideal case, it would be possible to obtain 100%
pure samples of EVs labelled with the LAF of choice (path
(b) in Figure 1). However, in this case, one would still face
challenges when studying the functional characteristics of
the EVs, e.g. in an internalization experiment. The inher-
ent dynamics of lipids [21,22] can lead to LAF spill over
from EVs into lipoproteins and plasma/serum proteins
including albumin (albumin contains multiple hydropho-
bic binding pockets [23]) when the purified LAF-labelled
EVs are exposed to a biological environment, such as
serum-containing growth medium or blood (path (c) in
Figure 1). We recently showed that highly stable artificial
vesicles (liposomes) labelled with commonly used LAFs
desorb a significant amount of their LAF content into
other plasma components and that the propensity of the
LAF to desorb from liposomes correlated with the degree
of cell staining in a liposome uptake study [13]. Such LAF
desorption is also expected fromEVs due to their similarity
with liposomes. Several physicochemical parameters dic-
tate to which degree the LAF desorption will take place
including (1) the ratio between the total EV membrane
area and the total “competing” membrane area from the
serum proteins, lipoproteins and cells, (2) the activation
barrier of the LAF to leave the EV and (3) the partitioning
of the LAF to EVs versus non-EV species.
When the LAF-labelled EV sample also contains LAF-
labelled lipoproteins either due to lipoprotein contamina-
tion of the isolated EV sample or due to the desorption of
LAFs from EVs into the lipoproteins after labelling, the
interpretation of EV uptake experiments relying on the
fluorescence from the dynamic LAF reporters becomes
practically impossible. Are we looking at uptake of EVs,
lipoproteins or both species? Along these lines, it should
be noted that the receptors which facilitate cholesterol
influx from lipoproteins into cells are overexpressed by
most tumour cells [20]. Thus in a cancer setting, an area
that the majority of the EV field is focused on, lipopro-
tein-based LAF accumulation interpreted as EVs is
a major issue. Further, many of the lipoprotein receptors
are naturally expressed in cells such as endothelial cells
and monocytes/macrophages – which are widely studied
for their ability to take up or scavenge EVs.
The amphiphilic nature of LAFs, like bare phospholi-
pids, drives the capability of the LAFs themselves to form
nanoparticles in solution (path (d) in Figure 1). A new
study showed that PKH26, a commonly used LAF to
label EVs form EV-sized PKH26 nanoparticles [12]. In
addition, we observed that di-8-ANEPPS (LAF), which
has been used to stain EVs, forms vesicular-like particles
with similar sizes (100 nm) to EVs, when mixed with
phosphate-buffered saline (manuscript in preparation).
LAF particles can potentially act as fluorescent ticking
“bombs” in an apparently purified EV sample because
they are likely to be self-quenched – the close proximity
between the LAF compounds in a LAF-particle can damp
the fluorescence brightness of each of the individual LAF
compounds. Conversely, when these LAF particles are
exposed to blood, serum and cells, the LAF compounds
may desorb from the LAF particles (by a similar mechan-
ism to the one shown in Figure 1 (path c)) and stain serum
Figure 1. Schematic illustration of the proposed paths of the lipid-anchored fluorophore (LAF) used for labelling and tracking EVs
that are discussed in this commentary.
(a) LAF labelling of non-EV serum components, that are often present in EV isolates, in addition to EV labelling. (b) LAF labelling of pure EVs. (c)
Dissociation of LAFs from EVs into serum components. (d) Formation of LAF particles that exhibit low fluorescence due to self-quenching.
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components and cells in a non-specific fashion. This will
lead to an increase in the fluorescence signal from the LAFs
due to dequenching and thereby complicate the tracking of
the actual LAF-labelled EVs. Several EV studies have
applied cell staining protocols to stain EVs. In many of
these cases, a huge excess of LAF compared to EV lipids are
used because the total amount of EV lipids (or total EV
surface) is much lower when compared to cells. The huge
excess of LAF can both lead to the formation of LAF
particle artefacts but also alter the overall structure and
function of the EVs if the EVs end up hosting
a significant amount of LAF in their membrane. On this
note, the LAF particles will not be removed by SEC or spin
filtration, when these traditional methods are applied to
remove non-EV-bound LAF compounds.
I suggest the following solutions to partly overcome
these not-so-known challenges shown in Figure 1. Path
(a): rather than using a single purification step based on
a physical method that separates species according to size
(size-exclusion chromatography), density (density gradient
centrifugation) or both (centrifugation) that has proven to
be inefficient [14,15], I have previously suggested employ-
ing a two-step procedure based on size and density separa-
tion to reduce the lipoprotein contamination in EV isolates
[16]. Recent studies have with some success applied this
two-step purification approach [24]. Another potential
strategy would be to use chemical/biological-based meth-
ods, such as immuno-precipitation. However, the lack of
a universal EV biomarker currently renders this approach
challenging too. Paths (a) and (d): it might be beneficial
(time- and yield-wise) to stain the EV sample prior to the
two-step EV-purification so that biological as well as free
and aggregated LAF contaminants will be simultaneously
removed. In cases when only a single-step purification
scenario is required or possible, I would recommend an
improved (high-resolution) SEC step compared to stan-
dard SEC, which should be efficient in removing the most
abundant lipoproteins including HDL and LDL from the
larger sized EVs. However, in this case the pure LAF
particles (if present) could co-elute with EVs. Path (c):
regarding the desorption of LAF from LAF-labelled EVs
into plasma components, I recommend using highly lipo-
philic LAF labels, i.e. lipid-anchors containing two long
alkyl/acyl chains since they interact more strongly with the
EV membrane than their less lipophilic counterparts. The
downside of using highly lipophilic compounds is their
strong tendency to form aggregates (LAF particles) and
hence their presence needs to be evaluated. The process of
post-inserting highly lipophilic compounds into EVs in
aqueous environment is a challenge in itself that is not
discussed in this commentary. The less lipophilic LAFs
(e.g. short chained acyl, alkyl or cholesterol anchored
fluorophore compounds) may be easier to post-insert
into EVs and to subsequently remove the free monomeric
or micellar LAFs. However, they complicate things in
a medium with a large reservoir of lipid surfaces beyond
the EVs including lipoproteins and cells that can compete
for the low partitioning LAFs. Thus, in the case of the less
lipophilic LAFs one will be confronted with the easy-in
/easy-out dynamic. To evaluate to what extent within the
relevant time frame a specific LAF is dissociating from the
LAF-labelled EVs in a biological environment, I propose to
use the high-resolution SEC analysis that our laboratory
recently reported [13].
To avoid the issues related to the dynamics of LAFs,
chemical staining of the less dynamic transmembrane-
bound EV-proteins could improve the specific staining of
EVs. However, this strategy could in some cases impair the
functionality of the EVs including their targeting properties
that are typically thought to bemediated by themembrane-
bound proteins. A completely different solution to over-
coming the LAF-related problems that is already used is the
transfection of cells to produceEVs containing a genetically
encoded fluorescent reporter, such as CD63-eGFP.
Although this approach can be specific, it may only
“label” a subpopulation of the EVs and the transfection/
labelling efficiency is low [25]. Additionally, this method is
relatively laborious and is readily applicable mainly to EVs
produced from cultured cells. Another approach to indu-
cing the parental cells to release fluorescently labelled EVs
is using a cytoplasmic dye, such as 5,6-carboxy-
succinimidyl-fluoresceine ester (CFSE). However, this
approach can lead to detrimental effects on the function
of immune cells [26] likely due to the impairment of
protein functions caused by the protein-cytoplasmic dye
conjugation.
As discussed above, the concerns related to the fluoro-
phore-reporters used to track EVs are many. Additionally,
the fluorescence-based techniques used to track these EVs/
fluorophore-reporters including confocal and flow cyto-
metry are limited by their inability to quantify what pro-
portion of the total EV population is internalized in cells. If
the actual percentage of EVs that are taken up by cells is
low, the concerns about non-EV LAF-labelled particle
uptake in these studies seem to be even more relevant.
This commentary highlights not-so-known pitfalls
related to the commonly used fluorophore-labelling of
EVs and provides tentative solutions to reduce the presence
of non-EV LAF-labelled particles for EV tracking studies.
We need to fully address and solve these challenges to
properly use LAF-labelled EVs to evaluate their targeting
and biological fate, so that we can reveal the true biological
functions of EVs and exploit their proposed clinical appli-
cations as a useful diagnostic tool and drug delivery system.
Additionally, this work illustrates that the EV field would
clearly benefit from a stronger collaboration between
JOURNAL OF EXTRACELLULAR VESICLES 3
biologists and chemists. Multifaceted expertise is needed to
address the intricate demands posed by EVs to ensure the
integrity of experimental designs and thus, the validity of
any conclusions about EVs.
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